Recombinant Human VEGFR2/KDR His-tag Protein, CF

Catalog #: 10964-KD Datasheet

Catalog #	Availability	Size / Price	Qty
10964-KD-050

Recombinant Human VEGFR2/KDR/Flk-1 His-tag Protein Bioactivity.

2 Images

All VEGFR2/KDR/Flk-1 Proteins and Enzymes

Product Details

FAQs

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGFR2/KDR His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87:1323. The ED₅₀ for this effect is 0.350-3.50 μg/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human VEGFR2/KDR/Flk-1 protein
Ala20-Glu764, with a C-terminal 6-His tag

Accession #

AAC16450.1

N-terminal Sequence
Analysis

Ala20

Predicted Molecular Mass

84 kDa

SDS-PAGE

114-126 kDa

Product Datasheets

10964-KD

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10964-KD

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 1.00 mg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human VEGFR2/KDR/Flk-1 His-tag Protein (Catalog # 10964-KD) inhibits the Recombinant Human VEGF₁₆₅ (293-VE) dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED₅₀ for this effect is 0.350-3.50 μg/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human VEGFR2/KDR His-tag Protein (Catalog # 10964-KD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 114-126 kDa.

Background: VEGFR2/KDR/Flk-1

Vascular endothelial Growth Factor Receptor 2 (VEGFR2), also known as FLK-1, KDR, and CD309, is a type I single-pass membrane receptor. Mature VEGFR2 contains a 745 amino acid extracelluar domain with seven immunoglobulin-like repeats, 21 transmembrane domain and 571 cytoplasmic domain. Within the extracellular domain, human VEGFR2 shares 80% homology with that of mouse and rat. VEGFR2, VEGFR1(Flt-1) and VEGFR3(Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors have almost exclusive expression in the endothelial cells and play essential roles in vasculogenesis and angiogenesis. VEGFR2 is the receptor for VEGF-A, VEGF-C, VEGF-D, and VEGF-E (viral homologs) (1, 2). Monomeric VEGFR2 dimerizes after binding to dimeric ligand and phosphorylate the Tyr in the cytoplasmic domain (3). VEGFR2 can also form heterodimer with VEGFR1 and VEGFR3 (4-6). Alternative splicing isoforms 2 and 3 which lack the transmembrane and cytoplasmic domains function as decoy receptors (7, 8). Targeting the signaling pathways of VEGFR1 and VEGFR2 are potential therapeutic targets for the treatment of inflammation and multiple tumors including breast, gastric, and lung carcinomas (9-12). Cancer immunotherapies using VEGF and VEGFR2 monoclonal antibodies may also be effective in combination with programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (13).

References

Ferra, N. and Davis-Smyth, T. (1997) Endocr. Rev. 18:4.
Wise, L.M. et al. (2012) Cell Microbiol. 13:1376.
Lepanen, V.M. et al. (2010) Proc. Natl. Acad. Sci. USA 107:2425.
Cai, M. et al. (2017) Vascul. Pharmacol. 88:11.
Nilsson, I. et al. (2010) EMBO J. 29:1377.
Dixelius, J. et al. (2003) J. Biol. Chem. 278:40973.
Albuquerque, R.J. et al. (2009) Nat. Med. 15:1023.
Jin, P. et al. (2008) Arthritis Res. Ther. 10:R73.
Shibuya, M. (2015) Endocr Metab Immune Disord Drug Targets. 15:135.
Farzaneh Behelgardi, M. et al. (2020), Mol Biol Rep. 47:2061.
Lian, L. et al. (2019) BMC Cancer. 19:183.
Hu, C. et al. (2019) Onco. Targets Ther. 12:933.
Gao, F. et al. (2020) Curr. Cancer Drug Targets. 20:3.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Alternate Names

CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2